XML 55 R29.htm IDEA: XBRL DOCUMENT
v3.20.1

Segment and Geographic Information | 12 Months Ended
--- | ---
Apr. 24, 2020
Segment Reporting [Abstract] |
Segment and Geographic Information | Segment and Geographic Information The Company’s organizational structure is based upon four principal operating and reportable segments: the Cardiac and Vascular Group, the Minimally Invasive Therapies Group, the Restorative Therapies Group, and the Diabetes Group. The Company's management has chosen to organize the entity based upon therapy solutions provided by each segment. The four principal segments are strategic businesses that are managed separately, as each one develops and manufactures products and provides services oriented toward targeted therapy solutions. The primary products and services from which the Cardiac and Vascular Group segment derives its revenues include products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease, as well as services to diagnose, treat, and manage heart- and vascular-related disorders and diseases. The primary products and services from which the Minimally Invasive Therapies Group segment derives its revenues include those focused on diseases of the respiratory system, gastrointestinal tract, renal system, lungs, pelvic region, kidneys, obesity, and other preventable complications. The primary products and services from which the Restorative Therapies Group segment derives its revenues include those focused on neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as various areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat. The primary products from which the Diabetes Group segment derives its revenues include those focused on diabetes management, including insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. Segment disclosures are on a performance basis, consistent with internal management reporting. Net sales of the Company's segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. There are certain corporate and centralized expenses that are not allocated to the segments. The Company's management evaluates the performance of the segments and allocates resources based on net sales and segment operating profit. Segment operating profit represents income before income taxes, excluding interest expense, amortization of intangible assets, centralized distribution costs, non-operating income or expense items, certain corporate charges, and other items not allocated to the segments. The financial information that is regularly reviewed by the Company's chief operating decision maker to assess performance and allocate resources changed during the first quarter of fiscal year 2020 to remove the impact of non-service pension and post-retirement benefit costs from segment results. This change did not have a material impact on the segment results reviewed. As a result of the change, the Company has revised the disclosures for the prior periods to align with the current presentation. The accounting policies of the segments are the same as those described in Note 1. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment. Segment Operating Profit
| Fiscal Year |  |  |  |
(in millions) | 2020 |  | 2019 |  | 2018
Cardiac and Vascular Group | $ | 3,719 |  |  | $ | 4,532 |  |  | $ | 4,461 |
Minimally Invasive Therapies Group | 3,044 |  |  | 3,262 |  |  | 3,346 |
Restorative Therapies Group | 2,915 |  |  | 3,319 |  |  | 3,058 |
Diabetes Group | 546 |  |  | 739 |  |  | 634 |
Segment operating profit | 10,224 |  |  | 11,852 |  |  | 11,499 |
Interest expense | (1,092) |  |  | (1,444) |  |  | (1,146) |
Other non-operating income, net | 356 |  |  | 373 |  |  | 170 |
Amortization of intangible assets | (1,756) |  |  | (1,764) |  |  | (1,823) |
Corporate | (1,239) |  |  | (1,291) |  |  | (1,211) |
Centralized distribution costs | (1,420) |  |  | (1,689) |  |  | (1,936) |
Restructuring and associated costs | (441) |  |  | (407) |  |  | (107) |
Acquisition-related items | (66) |  |  | (88) |  |  | (132) |
Certain litigation charges | (313) |  |  | (166) |  |  | (61) |
IPR&D charges | (25) |  |  | (58) |  |  | (46) |
Exit of businesses | (52) |  |  | (149) |  |  | — |
Debt tender premium and other charges | 7 |  |  | 28 |  |  | — |
Divestiture-related items | — |  |  | — |  |  | (115) |
Medical device regulations | (48) |  |  | — |  |  | — |
Contribution to Medtronic Foundation | (80) |  |  | — |  |  | (80) |
Gain on sale of businesses | — |  |  | — |  |  | 697 |
Hurricane Maria | — |  |  | — |  |  | (34) |
Income before income taxes | $ | 4,055 |  |  | $ | 5,197 |  |  | $ | 5,675 |
Total Assets and Depreciation Expense
| Total Assets |  |  |  | Depreciation Expense |  |  |  |
(in millions) | April 24, 2020 |  | April 26, 2019 |  | 2020 |  | 2019 |  | 2018
Cardiac and Vascular Group | $ | 14,844 |  |  | $ | 15,453 |  |  | $ | 210 |  |  | $ | 194 |  |  | $ | 183 |
Minimally Invasive Therapies Group | 39,666 |  |  | 41,186 |  |  | 194 |  |  | 206 |  |  | 217 |
Restorative Therapies Group | 16,850 |  |  | 16,825 |  |  | 233 |  |  | 217 |  |  | 146 |
Diabetes Group | 3,165 |  |  | 3,095 |  |  | 38 |  |  | 34 |  |  | 29 |
Segments | 74,525 |  |  | 76,559 |  |  | 675 |  |  | 651 |  |  | 575 |
Corporate | 16,164 |  |  | 13,135 |  |  | 232 |  |  | 244 |  |  | 246 |
Total | $ | 90,689 |  |  | $ | 89,694 |  |  | $ | 907 |  |  | $ | 895 |  |  | $ | 821 |
Geographic Information Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. Geographic property, plant, and equipment are attributed to the country based on the physical location of the assets. The following table presents net sales for fiscal years 2020, 2019, and 2018, and property, plant, and equipment, net at April 24, 2020 and April 26, 2019 for the Company's country of domicile, countries with significant concentrations, and all other countries:
| Net sales |  |  |  |  |  | Property, plant, and equipment, net |  |
(in millions) | 2020 |  | 2019 |  | 2018 |  | April 24, 2020 |  | April 26, 2019
Ireland | $ | 85 |  |  | $ | 91 |  |  | $ | 85 |  |  | $ | 164 |  |  | $ | 156 |
United States | 14,919 |  |  | 16,194 |  |  | 15,875 |  |  | 3,459 |  |  | 3,122 |
Rest of world | 13,909 |  |  | 14,272 |  |  | 13,993 |  |  | 1,205 |  |  | 1,397 |
Total other countries, excluding Ireland | 28,828 |  |  | 30,466 |  |  | 29,868 |  |  | 4,664 |  |  | 4,519 |
Total | $ | 28,913 |  |  | $ | 30,557 |  |  | $ | 29,953 |  |  | $ | 4,828 |  |  | $ | 4,675 |
No single customer represented over 10 percent of the Company’s consolidated net sales in fiscal years 2020, 2019, or 2018.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration